Home Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk
Article
Licensed
Unlicensed Requires Authentication

Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk

  • Jee-Soo Lee , JaYoon Gu , Hee Sue Park , Hyun Ju Yoo and Hyun Kyung Kim EMAIL logo
Published/Copyright: December 21, 2016
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 55 Issue 6

Abstract

Background:

Highly specific assays for measuring antiphospholipid antibodies (aPLs) are required for accurate assessment of thrombotic risk. aPLs against β2-glycoprotein I domain I (anti-β2GPIdI) and against prothrombin complexed with phosphatidylserine (anti-PS/PT) have been recently identified as being associated with a hypercoagulable state. This study evaluated the synergism between anti-β2GPIdI and anti-PS/PT for predicting thrombotic events.

Methods:

A total of 180 patients with clinical suspicion of hypercoagulability were evaluated. The plasma levels of lupus anticoagulant (LA) and antibodies against anticardiolipin (anti-CL) (IgG and IgM), β2GPI (IgG and IgM), PS/PT (IgG and IgM), and β2GPI dI (IgG) were measured.

Results:

IgG anti-β2GPIdI and LA were highly associated with thrombosis. Mean values and positivity rates of IgG anti-β2GPI dI and IgG anti-PS/PT were significantly higher in the triple-positive group (LA+, IgG anti-CL+, IgG anti-β2GPI+) than in the other groups. Interestingly, the thrombotic risk [odds ratio (OR) 24.400, 95% confidence interval (CI) 1.976–63.273, p<0.001] of the newly defined triple positive group (LA+, IgG anti-CL+, IgG anti-β2GPIdI+; OR 11.182, 95% CI 1.976–63.273, p=0.006) was more than twice that of the triple-positive group (LA+, IgG anti-CL+, IgG anti-β2GPI+). Double positivity for IgG anti-PS/PT and IgG anti-β2GPI also indicated significant thrombotic risk (OR 7.467, 95% CI 2.350–23.729, p=0.001). Furthermore, the thrombotic risk associated with double positivity for IgG anti-PS/PT and IgG anti-β2GPIdI was markedly elevated (OR 33.654, 95% CI 6.322-179.141, p<0.001).

Conclusions:

Our data suggest that simultaneous measurement of IgG anti-β2GPIdI and IgG anti-PS/PT may improve clinical decision-making for aPL-positive patients.

Keywords: antibodies; antiphospholipid; β2-glycoprotein I; phosphatidylserines; prothrombin; thrombosis
Corresponding author: Hyun Kyung Kim, MD, PhD, Department of Laboratory Medicine, Seoul National University College of Medicine, 101 Daehang-no Jongno-gu, Seoul 110-744, Republic of Korea, Phone: 82-2-2072-0853, Fax: 82-2-747-0359

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 2009;113:985–94.10.1182/blood-2007-12-129627Search in Google Scholar PubMed

2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.10.1111/j.1538-7836.2006.01753.xSearch in Google Scholar PubMed

3. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep 2007;9:212–8.10.1007/s11926-007-0034-xSearch in Google Scholar PubMed

4. Gomez-Puerta JA, Cervera R, Espinosa G, Aguilo S, Bucciarelli S, Ramos-Casals M, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006;35:322–32.10.1016/j.semarthrit.2005.07.003Search in Google Scholar PubMed

5. Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev 2010;9:200–2.10.1016/j.autrev.2009.04.001Search in Google Scholar PubMed

6. Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep 2012;14:71–8.10.1007/s11926-011-0227-1Search in Google Scholar PubMed

7. Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol 1990;93:771–5.10.1093/ajcp/93.6.771Search in Google Scholar PubMed

8. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004;104:3598–602.10.1182/blood-2004-03-1107Search in Google Scholar PubMed

9. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006;107:1916–24.10.1182/blood-2005-05-1943Search in Google Scholar PubMed

10. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014;13:917–30.10.1016/j.autrev.2014.05.001Search in Google Scholar PubMed

11. Oku K, Atsumi T, Amengual O, Koike T. Antiprothrombin antibody testing: detection and clinical utility. Semin Thromb Hemost 2008;34:335–9.10.1055/s-0028-1085475Search in Google Scholar PubMed

12. Manukyan D, Rossmann H, Schulz A, Zeller T, Pfeiffer N, Binder H, et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. Clin Chem Lab Med 2016;54:1663–70.10.1515/cclm-2016-0014Search in Google Scholar PubMed

13. Zhang S, Wu Z, Chen S, Li J, Wen X, Li L, et al. Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci Rep 2016;6:23839.10.1038/srep23839Search in Google Scholar PubMed PubMed Central

14. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737–40.10.1111/j.1538-7836.2009.03555.xSearch in Google Scholar PubMed

15. Chung Y, Kim JE, Lim HS, Kim HK. Clinical performance of anticardiolipin and antibeta2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods. Blood Coagul Fibrinolysis 2014;25:10–5.10.1097/MBC.0b013e32836466b5Search in Google Scholar PubMed

16. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL, et al. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014;12:792–5.10.1111/jth.12537Search in Google Scholar PubMed

17. Pelkmans L, de Laat B. Antibodies against domain I of beta2-glycoprotein I: the one and only? Lupus 2012;21:769–72.10.1177/0961203312437439Search in Google Scholar PubMed

18. de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011;13:70–6.10.1007/s11926-010-0144-8Search in Google Scholar PubMed PubMed Central

19. de Laat B, van Berkel M, Urbanus RT, Siregar B, de Groot PG, Gebbink MF, et al. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum 2011;63:3960–8.10.1002/art.30633Search in Google Scholar PubMed

20. Andreoli L, Nalli C, Motta M, Norman GL, Shums Z, Encabo S, et al. Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? Annals of the Rheumatic Diseases 2011;70:380–3.10.1136/ard.2010.137281Search in Google Scholar PubMed

21. Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, et al. Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015;13:782–7.10.1111/jth.12865Search in Google Scholar PubMed

22. Andreoli L, Chighizola CB, Nalli C, Gerosa M, Borghi MO, Pregnolato F, et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2-glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 2015;67:2196–204.10.1002/art.39187Search in Google Scholar PubMed

23. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009;7:1767–73.10.1111/j.1538-7836.2009.03588.xSearch in Google Scholar PubMed

24. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012;12:313–7.10.1016/j.autrev.2012.05.006Search in Google Scholar PubMed

25. De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-beta2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost 2016;14:1779–87.10.1111/jth.13389Search in Google Scholar PubMed

26. Pericleous C, Ferreira I, Borghi O, Pregnolato F, McDonnell T, Garza-Garcia A, et al. Measuring IgA Anti-beta2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One 2016;11:e0156407.10.1371/journal.pone.0156407Search in Google Scholar PubMed PubMed Central

27. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–63.10.1056/NEJMra002974Search in Google Scholar PubMed

28. Jaskowski TD, Wilson AR, Hill HR, Branch WD, Tebo AE. Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome? Clin Chim Acta 2009;410:19–24.10.1016/j.cca.2009.09.006Search in Google Scholar PubMed

29. Vlagea A, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost 2013;19:289–96.10.1177/1076029612437578Search in Google Scholar PubMed

30. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014;111:354–64.10.1160/TH13-06-0509Search in Google Scholar PubMed

31. Kim H, Kim JE, Hwang SM, Lee HR, Han KS, Kim HK. Synergistic thrombotic risk of antibodies against phosphatidylserine and prothrombin and beta-2-glycoprotein I. Clin Appl Thromb Hemost 2014;20:442–7.10.1177/1076029613497424Search in Google Scholar PubMed

32. Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 2006;91:699–702.Search in Google Scholar

33. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012;10:2512–8.10.1111/jth.12014Search in Google Scholar PubMed

34. Bertolaccini ML. Antibodies to prothrombin. Lupus 2012;21:729–31.10.1177/0961203312443299Search in Google Scholar PubMed

35. Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A, et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res 2013;56:432–8.10.1007/s12026-013-8421-zSearch in Google Scholar PubMed

Supplemental Material:

The online version of this article (DOI: 10.1515/cclm-2016-0676) offers supplementary material, available to authorized users.

Received: 2016-7-30
Accepted: 2016-11-1
Published Online: 2016-12-21
Published in Print: 2017-6-1

©2017 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Biotin interference on immunoassay methods: sporadic cases or hidden epidemic?
  4. Reviews
  5. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences
  6. Vitamin K plasma levels determination in human health
  7. Mini Review
  8. Point-of-care testing INR: an overview
  9. Opinion Paper
  10. Could accreditation bodies facilitate the implementation of medical guidelines in laboratories?
  11. Genetics and Molecular Diagnostics
  12. QMPSF is sensitive and specific in the detection of NPHP1 heterozygous deletions
  13. General Clinical Chemistry and Laboratory Medicine
  14. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference
  15. Multicenter performance evaluation of a second generation cortisol assay
  16. A rapid UPLC-MS/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum
  17. A microplate assay to measure classical and alternative complement activity
  18. Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2
  19. Retrospective evaluation of the clinical utility of serological biomarkers in Chinese patients with inflammatory bowel disease: 2-year clinical experience
  20. Infrared analysis of lipoproteins in the detection of alcohol biomarkers
  21. Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk
  22. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome
  23. Cardiovascular Diseases
  24. The impact of admission neutrophil-to-platelet ratio on in-hospital and long-term mortality in patients with infective endocarditis
  25. Letters to the Editor
  26. Biotin interference in immunoassays mimicking subclinical Graves’ disease and hyperestrogenism: a case series
  27. A simple method to detect biotin interference on immunoassays
  28. Proposed classification for a variant of Kounis syndrome
  29. Lyophilized hemoglobin E control material for the dichlorophenol-indophenol (DCIP) test
  30. Procalcitonin variation before and after 100-km ultramarathon
  31. Preliminary study in specific activity of molecular components in allergy: implications for diagnostics and relationship with disease severity
  32. A 2-min at 4500 g rather than a 15-min at 2200 g centrifugation does not impact the reliability of 10 critical coagulation assays
  33. Immunoassay interference caused by heterophilic antibodies interacting with biotin
  34. Red blood cell distribution width and mean platelet volume are potential prognostic indices for patients with primary biliary cirrhosis
  35. Neutrophil CD64 molecule expression can predict bloodstream infection in septic shock patients
https://doi.org/10.1515/cclm-2016-0676
Keywords for this article
antibodies; antiphospholipid; β2-glycoprotein I; phosphatidylserines; prothrombin; thrombosis

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Biotin interference on immunoassay methods: sporadic cases or hidden epidemic?
  4. Reviews
  5. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences
  6. Vitamin K plasma levels determination in human health
  7. Mini Review
  8. Point-of-care testing INR: an overview
  9. Opinion Paper
  10. Could accreditation bodies facilitate the implementation of medical guidelines in laboratories?
  11. Genetics and Molecular Diagnostics
  12. QMPSF is sensitive and specific in the detection of NPHP1 heterozygous deletions
  13. General Clinical Chemistry and Laboratory Medicine
  14. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference
  15. Multicenter performance evaluation of a second generation cortisol assay
  16. A rapid UPLC-MS/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum
  17. A microplate assay to measure classical and alternative complement activity
  18. Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2
  19. Retrospective evaluation of the clinical utility of serological biomarkers in Chinese patients with inflammatory bowel disease: 2-year clinical experience
  20. Infrared analysis of lipoproteins in the detection of alcohol biomarkers
  21. Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk
  22. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome
  23. Cardiovascular Diseases
  24. The impact of admission neutrophil-to-platelet ratio on in-hospital and long-term mortality in patients with infective endocarditis
  25. Letters to the Editor
  26. Biotin interference in immunoassays mimicking subclinical Graves’ disease and hyperestrogenism: a case series
  27. A simple method to detect biotin interference on immunoassays
  28. Proposed classification for a variant of Kounis syndrome
  29. Lyophilized hemoglobin E control material for the dichlorophenol-indophenol (DCIP) test
  30. Procalcitonin variation before and after 100-km ultramarathon
  31. Preliminary study in specific activity of molecular components in allergy: implications for diagnostics and relationship with disease severity
  32. A 2-min at 4500 g rather than a 15-min at 2200 g centrifugation does not impact the reliability of 10 critical coagulation assays
  33. Immunoassay interference caused by heterophilic antibodies interacting with biotin
  34. Red blood cell distribution width and mean platelet volume are potential prognostic indices for patients with primary biliary cirrhosis
  35. Neutrophil CD64 molecule expression can predict bloodstream infection in septic shock patients
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-0676/html
Scroll to top button